DrugPatentWatch

Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Generic Name: tolvaptan

Summary for Generic Name: tolvaptan

Tradenames:1
Patents:3
Applicants:1
NDAs:1
Drug Master File Entries: see list4
Suppliers: see list1
Formulation / Manufacturing:see details

Clinical Trials for: tolvaptan

Effects of Tolvaptan in Healthy Adults
Status: Recruiting Condition: Healthy

Bioavailability Study Comparing Tolvaptan Administered Via Nasogastric Tube to Tolvaptan Tablets Swallowed Intact
Status: Completed Condition: Healthy

Effect of the Diuretic Tolvaptan on Nitric Oxide System. A Dose-response Study (DOVA)
Status: Recruiting Condition: Nephropathy

A PK Study of 3 Dosages of Tolvaptan in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH)
Status: Recruiting Condition: Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH)

Post-Authorisation Safety Study of Samsca (Tolvaptan) Used in Routine Medical Practice
Status: Active, not recruiting Condition: SIADH; Non-SIADH Hyponatremia; Non-Hyponatremia

Phase III Study of Tolvaptan Tablet to Treat Cirrhosis Ascites
Status: Completed Condition: Ascites; Hepatic Cirrhosis

Randomized, Double-Blind, Placebo Controlled Study of the Short Term Clinical Effects of Tolvaptan in Patients Hospitalized for Worsening Heart Failure With Challenging Volume Management
Status: Recruiting Condition: Heart Failure

Efficacy and Safety of Tolvaptan in Cirrhotic Patients With Hyponatremia
Status: Recruiting Condition: Liver Cirrhosis; Hyponatremia

Effects of Tolvaptan vs Fluid Restriction in Hospitalized Subjects With Dilutional Hyponatremia
Status: Terminated Condition: Hyponatremia; Dilutional Hyponatremia; Inappropriate ADH Syndrome

Tolvaptan for Ascites in Cirrhotic Patients
Status: Recruiting Condition: Ascites; Cirrhosis

Courtesy of ClinicalTrials.org
See more clinical trials for this drug

Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Otsuka America Pharm
SAMSCA
tolvaptan
TABLET;ORAL022275May 19, 2009RXNo5,753,677<disabled>METHOD OF TREATING HYPONATREMIA
Otsuka America Pharm
SAMSCA
tolvaptan
TABLET;ORAL022275May 19, 2009RXNo5,258,510<disabled>YY
Otsuka America Pharm
SAMSCA
tolvaptan
TABLET;ORAL022275May 19, 2009RXNo8,501,730<disabled>Y
Otsuka America Pharm
SAMSCA
tolvaptan
TABLET;ORAL022275May 19, 2009RXNo<disabled>NEW CHEMICAL ENTITY
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011  2012  2013 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology

`abc